What You Should Know:
- Biopharma startup Rubedo Life Sciences raises $12M to develop a broad portfolio of innovative therapies engineered to target cells for chronic age-related diseases.
- Rubedo’s proprietary ALEMBIC™ drug discovery platform, has generated a novel pipeline of therapeutic candidates that selectively target senescent cells, pro-inflammatory and pro-fibrotic cell populations that result from a variety of cellular stress and damage.
Rubedo Life Sciences, a
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
UCB Taps Medisafe to Develop Branded Digital Drug Companions for Antiepileptic Medications
What You Should Know:
- UCB has selected Medisafe to develop branded digital
drug companions for antiepileptic medications, marking the company’s official
entry into the digital therapeutics space.
- The initial collaboration will primarily be focused on their antiepileptic medications, but they are exploring its use for additional brands.
Medisafe,
a leading digital
therapeutics company specializing in digital companions, has been selected
by UCB to develop branded digital
Read More
GE Healthcare Acquires Swedish Photon Counting CT Startup Prismatic Sensors AB
What You Should Know:
- GE Healthcare acquires Swedish startup Sensors AB, specializing
in photon counting detectors for an undisclosed amount.
- The acquisition underscores the company’s continued
investment and dedication in photon-counting CT technology (PCCT)
- PCCT is anticipated to further expand the clinical capabilities of traditional CT technology
GE Healthcare
today announced its acquisition
of Prismatic Sensors AB, a Swedish-based
startup specializing in photon
Read More
7 Best Practices for Third-Party Risk Management in the Pharmaceutical Industry
The globalization of the pharmaceutical industry has forced pharma companies to outsource, increasing their reliance on third-party vendors and suppliers. As this supply chain grows in complexity, companies find themselves grappling with a growing amount of cyber risk.
A data breach in the pharmaceutical industry can cost companies upwards of $5 million and costs can rise significantly if a third-party vendor or supplier is the cause of a data breach. For this reason, organizations must
Read More
FDA Authorizes First At-Home COVID-19 Test, Results in 30 Mins or Less
What You Should Know:
- FDA approves emergency use authorization (EUA) for Lucira
Health’s all-in-one-test kit for COVID-19 self-testing at home.
- The streamlined Lucira COVID-19 All-In-One Test Kit,
which fits in the palm of a hand, extracts genetic material from the virus and
amplifies it. This process takes up to 30 minutes, but a positive test result
can be generated in as few as 11 minutes.
On late Tuesday, the Food and Drug Administration (FDA) issued an emergency use
Read More
AstraZeneca, CCT Partner to Conduct COVID-19 Vaccine Clinical Trials in Arizona
What You Should Know:
- AstraZeneca and CCT announce a partnership to conduct
COVID-19 vaccine clinical trials in Arizona with 1,500 participants.
CCT Research (CCT), a leader in community-based, embedded clinical research, today announced its partnership with AstraZeneca to advance COVID-19 research. Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 COVID-19 VACCINE,
Read More
Peregrine Ventures Launches $300M VC Fund for Late-Stage Life Science Companies
What You Should Know:
- Israeli-based Peregrine Ventures launches a new $300 million venture capital fund named Peregrine Growth to focus on late-stage life science companies.
- Peregrine Growth will invest $20 to $30 million per funding round, with a strong emphasis on companies that are on the verge of an IPO or M&A.
Peregrine Ventures, one of Israel’s premier venture capital firms focused on the life sciences, today announced the launch of a new growth fund, Peregrine
Read More
FDA Awards Eli Lilly Emergency Use Authorization for Antibody to Treat COVID-19
What You Should Know:
- Eli Lilly is awarded Emergency Use Authorization (EUA) by the FDA for its monoclonal antibody for the treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients.
- U.S. government
will allocate 300,000 doses of bamlanivimab to high-risk patients, with no
out-of-pocket costs for the medication.
The U.S. Food and Drug Administration (FDA) today granted
Emergency Use Authorization (EUA) for Eli
Lilly and Company's (NYSE: LLY)
Read More
Cytek Biosciences Raises $120M To Expand Spectral Cell Analysis Systems
What You Should Know:
- Cytek Biosciences raises 120M in Series D funding –
underscoring the company’s growing momentum and significant contributions to
the field of cell analysis.
- Cytek, whose innovative flow cytometers represent the
first big technological leap in flow cytometry in decades, is currently
transitioning into a complete solution provider for the cell analysis market.
- This most recent funding round accelerates this transition and helps the company expand support for
Read More
Mammoth Lands 2 Major Partnerships to Use CRISPR to Solve COVID19 Testing Shortage, At Scale
What You Should Know:
- Mammoth Biosciences signs agreements
with MilliporeSigma and Hamilton company targeting commercialization of high-throughput
CRISPR-based SARS CoV-2 Test.
- These partnerships will help Mammoth bring a turnkey CRISPR-based sample-to-answer solution for commercial laboratories to enable a multi-fold increase in a testing capacity.
Mammoth
Biosciences, Inc., announced that it has signed agreements with
MilliporeSigma and Hamilton Company targeting
Read More
